NASDAQ:TFFP

TFF Pharmaceuticals Competitors

$11.36
-0.39 (-3.32 %)
(As of 04/20/2021 11:34 AM ET)
Add
Compare
Today's Range
$11.36
Now: $11.36
$11.84
50-Day Range
$12.07
MA: $14.30
$17.95
52-Week Range
$4.20
Now: $11.36
$21.14
Volume6,091 shs
Average Volume376,092 shs
Market Capitalization$262.87 million
P/E RatioN/A
Dividend YieldN/A
Beta2.47

Competitors

TFF Pharmaceuticals (NASDAQ:TFFP) Vs. NKTX, KNSA, ZGNX, MNKD, CNST, and PRAX

Should you be buying TFFP stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to TFF Pharmaceuticals, including Nkarta (NKTX), Kiniksa Pharmaceuticals (KNSA), Zogenix (ZGNX), MannKind (MNKD), Constellation Pharmaceuticals (CNST), and Praxis Precision Medicines (PRAX).

TFF Pharmaceuticals (NASDAQ:TFFP) and Nkarta (NASDAQ:NKTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

24.3% of TFF Pharmaceuticals shares are held by institutional investors. Comparatively, 77.1% of Nkarta shares are held by institutional investors. 10.4% of TFF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings for TFF Pharmaceuticals and Nkarta, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TFF Pharmaceuticals00403.00
Nkarta00503.00

TFF Pharmaceuticals currently has a consensus price target of $29.50, suggesting a potential upside of 152.14%. Nkarta has a consensus price target of $59.00, suggesting a potential upside of 83.51%. Given TFF Pharmaceuticals' higher possible upside, equities research analysts plainly believe TFF Pharmaceuticals is more favorable than Nkarta.

Valuation and Earnings

This table compares TFF Pharmaceuticals and Nkarta's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TFF PharmaceuticalsN/AN/A$-11,870,000.00($5.31)-2.14
NkartaN/AN/AN/AN/AN/A

Profitability

This table compares TFF Pharmaceuticals and Nkarta's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TFF PharmaceuticalsN/A-59.54%-57.08%
NkartaN/AN/AN/A

Summary

Nkarta beats TFF Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

TFF Pharmaceuticals (NASDAQ:TFFP) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

24.3% of TFF Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 10.4% of TFF Pharmaceuticals shares are owned by company insiders. Comparatively, 70.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for TFF Pharmaceuticals and Kiniksa Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TFF Pharmaceuticals00403.00
Kiniksa Pharmaceuticals00303.00

TFF Pharmaceuticals presently has a consensus price target of $29.50, suggesting a potential upside of 152.14%. Kiniksa Pharmaceuticals has a consensus price target of $37.00, suggesting a potential upside of 137.48%. Given TFF Pharmaceuticals' higher probable upside, analysts plainly believe TFF Pharmaceuticals is more favorable than Kiniksa Pharmaceuticals.

Earnings & Valuation

This table compares TFF Pharmaceuticals and Kiniksa Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TFF PharmaceuticalsN/AN/A$-11,870,000.00($5.31)-2.14
Kiniksa PharmaceuticalsN/AN/A$-161,870,000.00($2.99)-5.21

Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than TFF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TFF Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500.

Profitability

This table compares TFF Pharmaceuticals and Kiniksa Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TFF PharmaceuticalsN/A-59.54%-57.08%
Kiniksa PharmaceuticalsN/A-53.65%-49.11%

TFF Pharmaceuticals (NASDAQ:TFFP) and Zogenix (NASDAQ:ZGNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

24.3% of TFF Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.6% of Zogenix shares are owned by institutional investors. 10.4% of TFF Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Zogenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for TFF Pharmaceuticals and Zogenix, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TFF Pharmaceuticals00403.00
Zogenix01502.83

TFF Pharmaceuticals presently has a consensus price target of $29.50, suggesting a potential upside of 152.14%. Zogenix has a consensus price target of $58.25, suggesting a potential upside of 207.88%. Given Zogenix's higher probable upside, analysts plainly believe Zogenix is more favorable than TFF Pharmaceuticals.

Earnings & Valuation

This table compares TFF Pharmaceuticals and Zogenix's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TFF PharmaceuticalsN/AN/A$-11,870,000.00($5.31)-2.14
Zogenix$3.65 million279.90$-419,500,000.00($3.90)-4.70

TFF Pharmaceuticals has higher earnings, but lower revenue than Zogenix. Zogenix is trading at a lower price-to-earnings ratio than TFF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TFF Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500. Comparatively, Zogenix has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Profitability

This table compares TFF Pharmaceuticals and Zogenix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TFF PharmaceuticalsN/A-59.54%-57.08%
Zogenix-8,758.48%-53.91%-36.49%

Summary

Zogenix beats TFF Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

TFF Pharmaceuticals (NASDAQ:TFFP) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

24.3% of TFF Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.6% of MannKind shares are owned by institutional investors. 10.4% of TFF Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for TFF Pharmaceuticals and MannKind, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TFF Pharmaceuticals00403.00
MannKind00503.00

TFF Pharmaceuticals presently has a consensus price target of $29.50, suggesting a potential upside of 152.14%. MannKind has a consensus price target of $6.6250, suggesting a potential upside of 57.74%. Given TFF Pharmaceuticals' higher probable upside, analysts plainly believe TFF Pharmaceuticals is more favorable than MannKind.

Earnings & Valuation

This table compares TFF Pharmaceuticals and MannKind's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TFF PharmaceuticalsN/AN/A$-11,870,000.00($5.31)-2.14
MannKind$63.04 million16.59$-51,900,000.00($0.27)-15.56

TFF Pharmaceuticals has higher earnings, but lower revenue than MannKind. MannKind is trading at a lower price-to-earnings ratio than TFF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TFF Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500. Comparatively, MannKind has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500.

Profitability

This table compares TFF Pharmaceuticals and MannKind's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TFF PharmaceuticalsN/A-59.54%-57.08%
MannKind-71.92%N/A-46.80%

TFF Pharmaceuticals (NASDAQ:TFFP) and Constellation Pharmaceuticals (NASDAQ:CNST) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Profitability

This table compares TFF Pharmaceuticals and Constellation Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TFF PharmaceuticalsN/A-59.54%-57.08%
Constellation PharmaceuticalsN/A-28.88%-24.98%

Institutional and Insider Ownership

24.3% of TFF Pharmaceuticals shares are owned by institutional investors. 10.4% of TFF Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of Constellation Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for TFF Pharmaceuticals and Constellation Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TFF Pharmaceuticals00403.00
Constellation Pharmaceuticals02502.71

TFF Pharmaceuticals presently has a consensus price target of $29.50, suggesting a potential upside of 152.14%. Constellation Pharmaceuticals has a consensus price target of $45.2857, suggesting a potential upside of 107.54%. Given TFF Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe TFF Pharmaceuticals is more favorable than Constellation Pharmaceuticals.

Earnings & Valuation

This table compares TFF Pharmaceuticals and Constellation Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TFF PharmaceuticalsN/AN/A$-11,870,000.00($5.31)-2.14
Constellation PharmaceuticalsN/AN/A$-85,550,000.00($3.04)-7.10

Constellation Pharmaceuticals is trading at a lower price-to-earnings ratio than TFF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TFF Pharmaceuticals has a beta of 2.47, indicating that its stock price is 147% more volatile than the S&P 500. Comparatively, Constellation Pharmaceuticals has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500.

Summary

Constellation Pharmaceuticals beats TFF Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Praxis Precision Medicines (NASDAQ:PRAX) and TFF Pharmaceuticals (NASDAQ:TFFP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Praxis Precision Medicines and TFF Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxis Precision Medicines00403.00
TFF Pharmaceuticals00403.00

Praxis Precision Medicines presently has a consensus target price of $60.3333, suggesting a potential upside of 125.46%. TFF Pharmaceuticals has a consensus target price of $29.50, suggesting a potential upside of 152.14%. Given TFF Pharmaceuticals' higher possible upside, analysts clearly believe TFF Pharmaceuticals is more favorable than Praxis Precision Medicines.

Earnings and Valuation

This table compares Praxis Precision Medicines and TFF Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/AN/AN/AN/A
TFF PharmaceuticalsN/AN/A$-11,870,000.00($5.31)-2.14

Profitability

This table compares Praxis Precision Medicines and TFF Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Praxis Precision MedicinesN/AN/AN/A
TFF PharmaceuticalsN/A-59.54%-57.08%

Institutional and Insider Ownership

24.3% of TFF Pharmaceuticals shares are owned by institutional investors. 10.4% of TFF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

TFF Pharmaceuticals beats Praxis Precision Medicines on 3 of the 5 factors compared between the two stocks.


TFF Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NKTX
Nkarta
1.8$31.42-3.5%$1.07 billionN/A0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.57-0.6%$1.06 billionN/A-6.57Upcoming Earnings
Zogenix logo
ZGNX
Zogenix
1.7$18.33-3.2%$1.05 billion$3.65 million-1.93
MannKind logo
MNKD
MannKind
1.4$4.20-1.0%$1.04 billion$63.04 million-20.00Increase in Short Interest
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.59-0.2%$1.03 billionN/A-7.97
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$26.12-1.8%$1.03 billionN/A0.00News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.81-2.3%$1.02 billionN/A-6.52Increase in Short Interest
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$28.24-0.6%$1.02 billion$57.05 million0.00Analyst Report
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.73-1.2%$1.01 billion$800.40 million23.33
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$49.85-0.0%$1.01 billion$122.47 million-27.39
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.16-5.1%$992.09 million$120,000.00-3.39Analyst Report
News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$35.78-3.2%$970.00 million$20.79 million-12.34
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.12-2.8%$954.57 millionN/A-7.63
Prothena logo
PRTA
Prothena
2.1$22.39-6.1%$950.54 million$810,000.00-8.75
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$26.63-1.7%$941.57 millionN/A-12.27
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$13.77-40.7%$934.81 million$1.52 million-7.32Increase in Short Interest
News Coverage
Gap Down
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.90-0.1%$920.14 millionN/A0.00
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.19-1.5%$902.28 million$227.19 million44.97Analyst Downgrade
Radius Health logo
RDUS
Radius Health
1.3$18.41-2.7%$886.30 million$173.32 million-7.55
Ardelyx logo
ARDX
Ardelyx
1.6$8.26-6.7%$868.88 million$5.28 million-8.18Increase in Short Interest
Affimed logo
AFMD
Affimed
1.6$9.13-5.4%$849.70 million$23.96 million-15.47Earnings Announcement
Analyst Report
Analyst Revision
Merus logo
MRUS
Merus
1.8$21.78-1.5%$842.61 million$31.13 million-7.09
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$23.74-4.8%$840.11 millionN/A-21.98
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.06-1.4%$825.04 million$322.36 million121.86
Annexon logo
ANNX
Annexon
1.9$21.91-1.8%$821.16 millionN/A0.00
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$22.69-2.5%$818.85 million$296.70 million46.31Analyst Revision
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$32.34-2.5%$814.84 millionN/A-9.60News Coverage
Epizyme logo
EPZM
Epizyme
1.8$7.65-1.0%$786.80 million$23.80 million-3.43Analyst Report
News Coverage
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$20.70-1.7%$772.43 millionN/A0.00Increase in Short Interest
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.08-0.7%$751.39 million$148.36 million-7.03
Humanigen logo
HGEN
Humanigen
1.7$13.44-3.3%$742.87 millionN/A0.00Analyst Report
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.05-4.0%$709.73 million$6.83 million-19.64
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.81-0.6%$698.67 million$322.07 million-4.58Upcoming Earnings
Decrease in Short Interest
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.19-0.4%$692.81 million$40.89 million-3.17News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.08-1.9%$675.74 million$150,000.00-4.40News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.60-1.2%$671.97 million$19.56 million-19.14
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.57-2.7%$670.57 million$2.22 million-15.12News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.24-0.2%$666.59 million$252 million-2.07
Chimerix logo
CMRX
Chimerix
1.3$7.67-1.3%$665.73 million$12.52 million-13.46
Veru logo
VERU
Veru
1.4$8.88-2.4%$653.68 million$42.59 million-31.71Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.79-3.7%$650.06 million$17.26 million-4.11
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$28.19-0.3%$648.83 million$13.80 million-13.62Analyst Report
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.76-1.3%$637.44 million$5.09 million-6.27
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.04-4.1%$632.17 millionN/A-2.26Increase in Short Interest
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.28-5.2%$628.85 million$9.64 million-5.09
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.60-9.0%$616.02 millionN/A-4.26Analyst Upgrade
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.52-4.7%$604.18 million$143.01 million-1.05
OrganiGram logo
OGI
OrganiGram
1.6$2.40-8.3%$603.91 million$64.61 million-3.53Analyst Downgrade
Decrease in Short Interest
Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.90-0.7%$595.21 million$8 million-8.08
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.42-0.2%$592.94 millionN/A-9.80Analyst Report
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.